Cue biopharma reports second quarter 2020 results and cue-101 phase 1 dose escalation trial updates

Cue biopharma reports second quarter 2020 results and cue-101 phase 1 dose escalation trial updates.cue biopharma inc - as of june 30, had approximately $85 million in cash and marketable securities.cue biopharma inc - qtrly loss per share $0.38.

CUE Ratings Summary

CUE Quant Ranking